In this study, we aimed to investigate whether variation in metoprolol exposure determined by CYP2D6 genotype influenced the occurrence of MACE and cardiovascular (CV) death among post-MI patients using Mendelian randomization to test the null hypothesis of no association between genotype and cardiovascular events. Here, CYP2D6 is linked to myocardial infarction.